Tymlos Disease Interactions
There are 3 disease interactions with Tymlos (abaloparatide).
Parathyroid hormone/analogs (applies to Tymlos) hyperparathyroidism
Major Potential Hazard, Moderate plausibility. Applicable conditions: Hypercalcemia
Patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, should not be treated with parathyroid hormone and its analogs because of the risk of exacerbating hypercalcemia.
Parathyroid hormone/analogs (applies to Tymlos) malignancy
Major Potential Hazard, Moderate plausibility. Applicable conditions: Neoplasm of Bone, Paget's Disease
Parathyroid hormone and its analogs should not be used in patients who are at increased baseline risk for osteosarcoma. These agents should only be used if the potential benefits are considered to outweigh the potential risks. Monitor these patients according to clinical guidelines. Patients with bone metastases or a history of skeletal malignancies should not be treated with these agents.
Abaloparatide (applies to Tymlos) urolithiasis
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Nephrolithiasis
No dosage adjustment is required for patients with mild, moderate, or severe renal impairment. Patients with severe renal impairment may have increased abaloparatide exposure that may increase the risk of adverse reactions; therefore, monitor for adverse reactions. Abaloparatide may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or preexisting hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.
Switch to professional interaction data
Tymlos drug interactions
There are 4 drug interactions with Tymlos (abaloparatide).
More about Tymlos (abaloparatide)
- Tymlos consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (111)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: parathyroid hormone and analogs
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Prolia
Prolia (denosumab) is an injection that is administered subcutaneously (under the skin) once every ...
Fosamax
Fosamax (alendronate) is used to treat or prevent postmenopausal osteoporosis and steroid-induced ...
Evenity
Evenity (romosozumab) injection is used to treat osteoporosis in postmenopausal women to reduce the ...
Premarin
Premarin is used to treat symptoms of menopause such as hot flashes, and vaginal dryness. Learn ...
Reclast
Reclast (zoledronic acid) is used to treat osteoporosis in women after menopause and also to treat ...
Zometa
Zometa is used to treat high blood levels of calcium caused by cancer and multiple myeloma. Learn ...
Ibandronate
Ibandronate systemic is used for osteoporosis, prevention of osteoporosis
Raloxifene
Raloxifene systemic is used for breast cancer, prevention, osteoporosis, prevention of osteoporosis
Denosumab
Denosumab (Prolia, Conexxence, Jubbonti, Ospomyv, and Stoboclo brands/biosimilars) is used to treat ...
Calcium/vitamin d
Calcium/vitamin d systemic is used for dietary supplementation, osteoporosis
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.